A Phase 1C, open-label, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of DM199 administered IV with PVC bag in adult healthy participants and adults recently taking ACE inhibitors
Latest Information Update: 21 Aug 2023
At a glance
- Drugs Rinvecalinase alfa (Primary)
- Indications Renal failure; Stroke; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors DiaMedica Therapeutics
Most Recent Events
- 14 Aug 2023 According to DiaMedica Therapeutics media release, the company completed an additional cohort of hypertensive patients (Part B) being treated with angiotensin-converting enzyme inhibitors (ACEi). This Phase 1C study is now finished and the Company is completing final closing procedures.
- 05 Jun 2023 Planned End Date changed from 30 Jun 2023 to 31 Jul 2023.
- 15 May 2023 According to DiaMedica Therapeutics media release, the results from this study will be included as additional supporting data in the Company's clinical hold response package to the FDA.